Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

• Job P van Kooten,
• Jacobus W A Burger,
• Cornelis Verhoef,
• Joachim G J V Aerts,
• Eva V E Madsen,
• Alexandra R M Brandt-Kerkhof,
• Stijn L W Koolen,
• Ron H J Mathijssen,
• Michelle V Dietz,
• Niels A D Guchelaar

Affiliations

Job P van Kooten

Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands

Jacobus W A Burger

1 Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Cornelis Verhoef

Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands

Joachim G J V Aerts

Pulmonary Medicine, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands

Eva V E Madsen

Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands

Alexandra R M Brandt-Kerkhof

1 Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Stijn L W Koolen

2 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Ron H J Mathijssen

Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands

Michelle V Dietz

Department of Surgical Oncology, Erasmus MC Kanker Instituut, Rotterdam, The Netherlands

Niels A D Guchelaar

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands